VPS37A and colorectal carcinoma: Therefore, in CRC patients with VPS37A deficiency, a multimodal therapeutic strategy could be designed to synergistically dismantle treatment resistance by orchestrating metabolic stress induction, tumor suppressor reconstitution, and oncogenic receptor degradation.